HIV/AIDS Vaccine Development
$2,367,571Z01FY2007AINIH
Niaid Extramural Activities
Investigators
Linked publications & trials
Paper 23388006Paper 19420074Paper 17391815Paper 17325604Paper 17113201Paper 17109336Paper 16943292Paper 16763152Paper 16735692Paper 16622001Paper 16569729Paper 15994776Paper 15956548Paper 15858035Paper 15837367Paper 15795244Paper 15761255Paper 15709015Paper 15613305Paper 15596858Paper 15220422Paper 15128818Paper 15047819Paper 14985706Paper 14610198Paper 12928404Paper 12885892Paper 11991964Paper 11739689Paper 11312370
Abstract
During the past year, the VRC's Vector Core created and tested new vaccine vectors expressing different HIV protein, including structural and envelope proteins. In addition,different methods and routes of administration as well as prime/boost combinations were tested to further optimize HIV vaccine strategies. New adenoviral and BCG vectors were tested, as well as administration via intradermal and mucosal delivery. Several candidate vaccines elicited promising immunogenicity data in preliminary studies and are being tested further.
View original record on NIH RePORTER →